The network and balance of cytokines is of major importance in maintaining proper homeostasis of hematopoiesis. Abnormalities in this network may result in a variety of blood disorders; however, the role of this network is not clear in leukemia. The use of antineoplastic agents has improved the survival rate of some types of leukemia, and adjunctive therapy with cytokines may be helpful. Chemotherapeutic approaches are no longer the best choice because cytotoxicity may affect normal and leukemic cells, and leukemic cells may develop resistance to the chemotherapeutic agent. Induction of differentiation to a mature phenotype and the control of apoptotic-gene expression have provided other possible alternative therapies. Combined effects of cytokines and vitamin derivatives such as retinoic acid (RA) and 1, 25 dihydroxyvitamin D3 (VD3) were found more beneficial than any of these agents individually. These agents exhibit cooperative effects, potentiate each other's effects, or both. Therefore, understanding the hematopoietic actions of these agents, their interactions with their receptors, and their differentiation signaling pathways may result In the design of new therapies. However, the role of cytokines in apoptosis is controversial because in some cases they were found to increase tumor cell resistance to apoptosis-inducing agents. Recent studies in the molecular biology of gene regulation, transcription factors, and repressors have led to new possible approaches such as differentiation therapy for the treatment of leukemia. In addition, the development of drugs that act on the molecular level such as imatinib is just the beginning of a new era in molecular targeted therapy in which the drug acts specifically on the leukemic cell. There are many possible combinations of cytokines, retinoids, and VD3, and perhaps the best therapeutic combination is yet to be described. This minireview is an update on the role of cytokines and the therapeutic potential of combinations with agents such as RA, VD3, and other chemotherapeutic agents.
MoqattashSLuttonJD. Leukemia cells and the cytokine network: a review of the literature. Proc Soc Exp Biol Med219:8–27, 1998.
2.
PlataniasIXFishEN. Signaling pathways activated by interferons. Exp Hematol27:1583–1592, 1999.
3.
WeekxSFVan BockstaeleDRPlumJMoulijinARodrigusILardonFDe SmedtMNijsGLenjouMLoquetPBernemanZNSnoeckHW. CD34+ CD38- and CD34+ CD38+ human hematopoietic progenitors from fetal liver, cord blood, and adult bone marrow respond differently to hematopoietic cytokines depending on the ontogenic source. Exp Hematol26:1034–1042, 1999.
4.
HarengLHartungT. Induction and regulation of endogenous granulocyte colony-stimulating factor formation. Biol Chem383: 1501–1517, 2002.
5.
SuzukiMHarashimaAOkochiAYamamotoMMatsuoYMotodaRYoshiokaTOritaK. Transforming growth factor-ß1 augments granulocyte-macrophage colony-stimulating factor-induced proliferation of umbilical cord blood CD34+ cells with an associated tyrosine phosphorylation of STATS. Exp Hematol30:1132–1138, 2002.
6.
KotenkoSV. The family of IL-10-related cytokines and their receptors: related, but to what extent?Cytokine Growth Factor Rev13:223–240, 2002.
7.
BaetuTMHiscottJ. On the TRAIL to apoptosis. Cytokine Growth Factor Rev13:199–207, 2002.
8.
SachsL. The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci U S A93:4742–4749, 1996.
9.
XiaoWKoizumiKNishioMEndoTOsawaMFujimotoKSatoISakaiTKoikeTSawadaK. Tumor necrosis factor-α inhibits generation of glycoprotein A+ cells by CD34+ cells. Exp Hemalol30: 1238–1247, 2002.
10.
LotemJSachsL. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene13:3284–3294, 2002.
11.
BorishLCSteinkeJW. Cytokines and chemokines. J Allergy Clin Immunol111:S460–S475, 2003.
12.
ShenJTFalangaV. Growth factors, signal transduction, and cellular responses. J Dermatol30:5–16, 2003.
13.
MoseleyTAHaudenschildDRRoseLReddiAH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev14:155–174, 2003.
14.
MiyamotoMPrauseOSjostrandMLaanMLotvallJLindenA. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. Immunol170:4665–4672, 2003.
15.
AggarwalSGumeyAL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol7:1–8, 2002.
16.
Maguer-SattaVBartholinLJeanpierreSFfrenchMMattelSMagaudJPRimokhR. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGF-beta family. Exp Cell Res282:110–120, 2003.
17.
SaitoMKiyokawaNTagachiTSuzukiKSekinoTMimoriKNakajimaHKatagiriYFujimuraJFujitaHIshimatoKYamashiroYJunichiroF. Granulocyte colony-stimulating factor directly affects human monocytes and modulates cytokines secretion. Exp Hematol30:1115–1123, 2002.
18.
BolwellBJFishlederAAndersonSWLichtinAEKooAYanssensTBurwellRBauccoPGreenR. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplant12:609–614, 1993.
19.
JohnsonBSMuellerLSiJCollinsSJ. The cytokines IL-3 and GM-CSF regulate the transcriptional activity of retinoic acid in different in vitro models of myeloid differentiation. Blood99:746–753, 2002.
20.
CarslanjenDRegenfusMMullerCSalamaA. Interleukin-6 is a major effector molecule of short-term G-CSF treatment inducing bone metabolism and an acute phase response. Exp Hematol29:812–821, 2001.
21.
OkumaEInazawaYSaekiKYouA. Potential role of extracellular signal-regulated kinase but not p38 during myeloid differentiation of U937 cells stimulated by cytokines: augmentation of differentiation via prolonged activation of extracellular signal-regulated kinase. Exp Hematol30:571–581, 2002.
22.
ShimizuTTakedaK. Induction of retinoic acid receptor-alpha by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines. Cancer Res60:4544–4549, 2000.
23.
ReillyJT. FLT3 and its role in the pathogenesis of acute myeloid leukemia. Leuk Lymphoma44:1–7, 2003.
24.
KarsunkyHMeradMCozzioAWeissmanILManzMG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med198:305–313, 2003.
25.
BruserudOHovlandRWergelandLHuangTSGjertsenBT. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica88:416–428, 2003.
26.
LapidotTPetitI. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines and stromal cells. Exp Hematol30:973–981, 2002.
27.
ReissM. Transforming growth factor and cancer. Microbes and Infection15:1327–1347, 1999.
28.
BollagW. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1, 25-dihydroxyvitamin D3, and analogues. J Cell Biochem56:427–435, 1994.
29.
MoqattashSAbrahamNGLuttonJD. Modulation of growth supporting and oncogenic properties of murine leukemia cells. Leuk Res18:531–539, 1994.
30.
MotomuraKSakaiHIsobeHNawataH. Effects of retinoids on the production of tumour necrosis factor-alpha and nitric oxide by lipopolysaccharide-stimulated rat Kupffer cells in vitro: evidence for participation of retinoid X receptor signaling pathway. Cell Biochem Funct15:95–101, 1997.
31.
TakedaKAkiraS. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev11:199–207, 2000.
32.
BollagW. Retinoids and interferon: a new promising combination. Br J Haematol79:87–91, 1991.
33.
NakaTNishimotoNKishimotoT. The paradigm of IL-6: from basic science to medicine. Arthritis Res4(Suppl 3):S233–S242, 2002.
34.
NakashimaKRagaT. gp130 and the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities. Semin Hematol35:210–221, 1999.
35.
DuitsAJDimjatiWVan de WinkelJGJCapelPJA. Synergism of interleukin 6 and 1, 25-dihydroxyvitamin D3 in induction of myeloid differentiation of human leukemic cell lines. J Leukoc Biol51:237–243, 1992.
36.
GorgunGFossF. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood100:1399–1403, 2002.
37.
DrewEMerkensHChelliahSDoyonnasRMcNagnyKM. CD34 is a specific marker of mature murine mast cells. Exp Hematol30:1211–1218, 2002.
38.
TakaiKHaraJMatsumotoKHosoiGOsugiYTawaAOkadaSNakamuraT. Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood89:1560–1565, 1997.
39.
FujikiHKimuraTMinamiguchiHHaradaSWangJNakaoMYokotaSUrataYUedaYYamagishiHSonodaY. Role of human Interleukin-9 as a megakaryocyte potentiator in culture. Exp Hematol30:1373–1380, 2002.
40.
GounniASGregoryBNutkuEArisFLatifaKMinshallENorthJTavernierJLevitRNicolaidesNRobinsonDHamidQ. Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood96:2163–2171, 2000.
41.
SachsL. The cellular and molecular environment in leukemia. Blood Cells19:709–730, 1993.
42.
LaiRO'brienSMaushouriTRogersAKantarjianHKeatingMAlbitarM. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer95:1071–1075, 2002.
43.
ZhouRSunGWuW. The effect of sera of acute promyelocytic leukemia patients and culture supernatants of NB4 cells on normal granulo–macrophage hematopoiesis. Zhonghua Xue Ye Xue Za Zhi20:343–346, 1999.
44.
RamshawHSBardyPGLeeMALopezAF. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol30:1124–1131, 2002.
45.
ZweirzinaHSchollenbergerSHeroldMSchmalzlFBezemerJ. Endogenous serum levels and surface receptors of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leuk Res17:1181–1186, 1992.
46.
ManakovaTETsvetaevaNVLevinaAAMomotyukKSSarkisyanGPKhoroshkoNDGerasimovaLP. In vivo production of cytokines by bone marrow stromal cells and macrophages from patients with myelodysplastic syndrome. Bull Exp Biol Med132:633–636, 2001.
47.
EmanuelPDBatesLJCastleberryRPGualtieriRJZuckermanKS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic Progenitors. Blood77:925–929, 1991.
48.
RossiFMDeganMTassan MazzoccoLDi FranciaRAldinucciDPolettoDVellengaEPintoAGatteiV. Co-expression of CD30L and interleukin-4 (IL-4) receptors by acute myeloid leukemia blasts is associated with the expression of IL-4-producing CD30+ normal T cells. Br J Hematol117:59–69, 2002.
49.
AldinucciDPolettoDNanniPDeganMRupoloMPintoAGatteiV. CD40L induces proliferation, self-renewal, rescue from apoptosis and production of cytokines by CD40-expressing AML blasts. Exp Hematol30:1283–1292, 2002.
50.
DimbergABahramFKarlbergILarssonLGNilssonKObergF. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27 (Kipl). Blood99:2199–2206, 2002.
51.
EgyedMMihalyfalviZKollarBRumiGKellerEVassJFeketeS. Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon. Orv Hetil142:2421–2425, 2001.
52.
StagnoFGuglielmoPConsoliUFiumaraPLongoGSGiustolisiR. All-trans-retinoic-acid- and growth-factor-mediated induction of alkaline phosphatase activity in freshly isolated chronic myeloid leukemia cells. Acta Haematol102:61–65, 1999.
53.
LiuJGuoLLuoYLiJWLiH. All trans-retinoic acid suppresses in vitro growth and down-regulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. Anticancer Res20:2659–2664, 2000.
54.
WuWSunGWuWZhouRLiXShenZWangZ. The relationship between the levels of granulocyte colony-stimulating factor and leukocytosis induced by all-trans retinoic acid in acute promyelocytic leukemia. Chin Med J (Engl)12:1085–1087, 1999.
55.
GanserASeipeltGVerbeekWOttmannOGMaurerAKolbeKHessUEisnerSReutzelRWormannB. Effect of combination therapy with all trans retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 19948:369–375, 1994.
56.
HiroichiNSatokoMKeikoBYukoTTingWSatoruNKoichiS. Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice. Pharmacology58, 101–112, 1999.
57.
PeckRBollaW. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer27:153–157, 1991.
FedericiABStabileFCastamanG. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood92:2707–2711, 1998.
60.
WightmanJRobersonMSLamkinTJVarvayanisSYenA. Retinoic acid-induced growth arrest and differentiation: retinoic acid up-regulates CD32 (Fc gammaRII) expression, the ectopic expression of which retards the cell cycle. Mol Cancer Ther1:493–506, 2002.
61.
BattleTEYenA. Ectopic expression of CXCR5/BLR1 accelerates retinoic acid- and vitamin D(3)-induced monocytic differentiation of U937 cells. Exp Biol Med (Maywood)227:753–762, 2002.
62.
BattleTELevineRAYenA. Retinoic acid-induced blr1 expression promotes ERK2 activation and cell differentiation in HL-60 cells. Exp Cell Res254:287–298, 2000.
63.
YenAPlacanicaLBloomSVarvayanisS. Polyomavirus small t antigen prevents retinoic acid-induced retinoblastoma protein hypophosphorylation and redirects retinoic acid-induced G0 arrest and differentiation to apoptosis. J Virol75:5302–5314, 2001.
64.
MannervikMNibuYZhangHLevineM. Transcriptional coregulators in development. Science284:606–609, 1999.
65.
BattleTERobersonMSZhangTVarvayanisSYenA. Retinoic acid-induced blr1 expression requires RAR-α, RXR, and MAPK activation and uses ERK2 but not JNK/SAPK to accelerate cell differentiation. Eur J Cell Biol80:59–67, 2001.
66.
BhatiaMKirklandJBMeckling-GillKA. 1, 25-Dihydroxyvitamin D3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Exp Cell Res222:61–69, 1996.
67.
SharonSYWilliamsMANewlandACColstonKW. Leukemia cell differentiation, cellular and molecular interactions of retinoids and vitamin D. Gen Pharmacol32:143–154, 1999.
68.
SongXNormanAW. l, Alpha, 25-dihydroxyvitamin D3 and phorbol ester mediate the expression of alkaline phosphatase in NB4 acute promyelocytic leukemia cells. Leuk Res22:69–76, 1998.
69.
KanekiMInoueSHosoiTMizunoYAkedoYIkegamiANakamuraTShirakiMItoHSuzuS. Effects of 1 alpha, 25-dihydroxyvitamin D3 on macrophage colony-stimulating factor production and proliferation of human monocytic cells. Blood83: 2285–2293, 1994.
70.
SongXDNormanAW. Bryostatin-1 and 1, alpha, 25-dihydroxyvitamin D3 synergistically stimulate the differentiation of NB4 acute promyelocytic leukemia cells. Leukemia13:275–281, 1999.
71.
GrandeAMontanariMTagliaficoEManfrediniRMaraniTZSienaMTenediniEGallinelliAFerrariS. Physiological levels of 1, alpha, 25 dihydroxyvitamin D3 induce the monocytic commitment of CD34+ hematopoietic progenitors. Leukoc Biol71:641–651, 2002.
72.
LotemJSachsL. Epigenetics wins over genetics: induction of differentiation in tumor cells. Semin Cancer Biol12:339–346, 2002.
73.
AlonDBChaimovitzCDvilanskiALugassyGDouvdevaniAShanySNathanI. Novel role of l, 25(OH)2 vitamin D3 in induction of erythroid progenitor cell proliferation. Exp Hematol30:403–409, 2002.
74.
JakubowiakACammengaJSokolicRAlvarezSJacksonGHedvatCNimerS. Molecular biology of leukemia. Curr Oncol Rep2:123–131, 2000.
75.
JordanCT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia16:559–562, 2002.
76.
JordanCTUpchurchDSzilvassySJGuzmanMLHowardDSPettigrewALMeyerroseTRossiRGrimesBRizzieriDALugerSMPhillipsGL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia14:1777–1784, 2000.
77.
GrignaniFDe MatteisSNerviC. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature391:815–818, 1998.
78.
WongCWPrivalskyML. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RAR-alpha, and BCL-6. J Biol Chem273:27695–27702, 1998.
79.
GelmettiVZhangJFanelliM. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol18:7185–7191, 1998.
80.
FenrickRAmannJMLutterbachB. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol19:6566–6574, 1999.
81.
LutterbachBWestendorfJJLinggiB. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol18:7176–7184, 1998.
82.
FenrickRAmannJMLutterbachB. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol19:6566–6574, 1999.
83.
PuccettiEObradovicDBeissertTBianchiniAWashburnBChiaradonnaFBoehrerSHoelzerDOttmannOGPelicciPGNerviCRuthardtM. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res62:7050–7058, 2002.
84.
LinRJNagyLInoueS. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature391:811–814, 1998.
85.
BhatAKolibabaKOdaTOhno-JonesSHeaneyCDrukerBJ. Interaction of CBL with BCR-ABL and CRKL in BCR-ABL transformed myeloid cells. J Biol Chem272:16170–16175, 1997.
86.
BeyermannBAdamsHPHenzeG. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. J Clin Oncol15:2231–2237, 1997.
87.
SchifferCAHehlmannRLarsonR. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL. Leukemia17:691–699, 2003.
88.
BadranAYoshidaAWanoYImamuraSKawaiYTsutaniHInuzukaMUedaT. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res23:589–592, 2003.
89.
CharbordPOostendorpRPangWHéraultONoelFTsujiTDzierzakEPéaultB. Comparative study of stromal cell lines derived from embryonic, fetal, and postnatal mouse blood-forming tissue. Exp Hematol30:1202–1210, 2002.
90.
DeryuginaEIMuller-SieburgCE. Stromal cells in long-term cultures: keys to the elucidation of hematopoietic development. Crit Rev Immunol13:115–150, 1993.
91.
GidaliJLaszloEHalmGFeherI. Blast colony-forming cell binding from CML bone marrow, or blood, on stromal layers pretreated with G–CSF or SCF. Cell Prolif35:1–7, 2002.
92.
BlazsekIDelmas MarsaletBLegrasSMarionSMachoverDMissetJL. Large scale recovery and characterization of stromal cell-associated primitive haemopoietic progenitor cells from filter-retained human bone marrow. Bone Marrow Transplant23:647–657, 1999.
93.
BlazsekIFarabosCQuittetPLabatMLBringuierAFTrianaBKMachoverDReynesMMissetJL. Bone marrow stromal cell defects and 1 alpha, 25-dihydroxyvitamin D3 deficiency underlying human myeloid leukemias. Cancer Detect Prev20:31–34, 1996.
94.
MayaniH. Composition and function of the hemopoietic micro–environment in human myeloid leukemia. Leukemia10:1041–1047, 1996.
95.
Flores-FigueroaEGutierrez-EspindolaGMontesinosJJArana-TrejoRMMayaniH. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res26:677–686, 2002.
YuanXMLiWDalenHLotemJKamaRSachsLBrunkUT. Lysosomal destabilization in p53-induced apoptosis. Proc Natl Acad Sci U S A99:6286–6291, 2002.
98.
LotemJSachsL. Cytokines as suppressors of apoptosis. Apoptosis4:187–196, 1999.
99.
DupreySPBoettingerD. Developmental regulation of c-myb in normal myeloid progenitor cells. Proc Natl Acad Sci U S A82:6937–6941, 1985.
100.
FuSLLipsickJS. Constitutive expression of full-length c-Myb transforms avian cells characteristic of both the monocytic and granulocytic lineages. Cell Growth Differ8:35–45, 1997.
101.
WolffLSchmidtMKollerRHaviemikPWatsonRBiesJMaciagK. Three genes with different function in transformation are regulated bv c-mvb in myeloid cells. Blood Cells Mol Dis27:483–488, 2001.
102.
YiHKNamSYKimJCKimJSLeeDYHwangPH. Induction of apoptosis in K562 cells by dominant negative c-myb. Exp Hematol30:1139–1146, 2002.
103.
JosefsenDBlomhoffHKLomoJBlystadAKSmelandEB. Retinoic acid induces apoptosis of human CD34+ hematopoietic progenitor cells: involvement of retinoic acid receptors and retinoid X receptors depends on lineage commitment of the hematopoietic progenitor cells. Exp Hematol27:642–653, 1999.
104.
KetleyNJAllenPDKelseySMNewlandAC. Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, l, 25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. Blood90:4578–4587, 1997.
105.
BraunSGerhartzHHSchmetzerHM. Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro. Haematologia (Budap)30:271–288, 2000.
106.
BraunSWGerhartzHHSchmetzerHM. Influence of cytokines and autologous lymphokine-activated killer cells on leukemic bone marrow cells and colonies in AML. Acta Haematol105:209–221, 2001.
107.
MeloniGTrisoliniSMCapriaSTorelliGFBaldacciETorromeoCValesiniGMandelliF. How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia16:2016–2018, 2002.
108.
Chambaut-GuerinAMCostaSLLefrancoisTFagesCGauthereauXTardyM. Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells. Neuroreport11:389–393, 2000.
109.
XiePChanFSIpNYLeungMF. IL-6 enhanced the retinoic acid-induced differentiation of human acute promyelocytic leukemia cells. Cancer Lett148:207–213, 2000.
110.
ShimizuTTakedaK. Induction of retinoic acid receptor-alpha by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines. Cancer60:4544–4549, 2000.
111.
VisaniGOttavianiEZauliGTosiPPellacaniAIsidoriAPierpaoliSTuraS. All-trans retinoic acid at low concentrations directly stimulates adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. Eur J Haematol63:149–153, 1999.
112.
GrandeAManfrediniRTagliaficoEBalestriRPizzanelliMPapaSZucchiniPBonsiLBagnaraGTorelliU. All-trans-retinoic acid induces simultaneously granulocytic differentiation and expression of inflammatory cytokines in HL-60 cells. Exp Hematol23:117–125, 1995.
113.
SteinerMPrielIGiatJLevyJSharoniYDanilenkoM. Carnosic acid inhibits proliferation and augments differentiation of human leukemic cells induced by 1, 25-dihydroxyvitamin D3 and retinoic acid. Nutr Cancer41:135–144, 2001.
114.
DoreBTUskokovicMRMomparlerRL. Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogues. Leuk Res20:761–769, 1996.
115.
TaimiMBreitmanTR. Growth, differentiation, and death of retinoic acid-treated human acute promyelocytic leukemia NB4 cells. Exp Cell Res10: 230: 69–75, 1997.
116.
GuzeyMKitadaSReedJC. Apoptosis induction by 1α, 25 dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther1:667–677, 2002.
117.
WightmanJRobersonMSLamkinTJVarvayanisSYenA. Retinoic acid-induced growth arrest and differentiation: retinoic acid up-regulates CD32 (Fc γRII) expression, the ectopic expression of which retards the cell cycle. Mol Cancer Ther1:493–506, 2002.
118.
CoyneDWGrieffMAhyaSNGilesKNorwoodKSlatopolskyE. Differential effects of acute administration of 19-Nor-1, 25-dihydroxyvitamin D2 and 1, 25-dihydroxyvitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis40:1283–1288, 2002.
119.
FenauxPDe BottonS. Retinoic acid syndrome. Recognition, prevention and management. Drug Saf18:272–279, 1998.
120.
HsuHCTsaiWHChenPGHsuMLHoCKWangSY. In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemia cells. Eur J Hematol63:11–18, 1999.
121.
ShibakuraMNiiyaKKiguchiTShinagawaKIshimaruFIkedaKNambaMNakataYHaradaMTanimotoM. Simultaneous induction of matrix metalloproteinase-9 and interleukin 8 by all-trans retinoic acid in human PL-21 and NB4 myeloid leukaemia cells. Br J Haematol118:419–425, 2002.
122.
BertagnoloVMarchisioMPierpaoliSColamussiMLBrugnoliFVisaniGZauliGCapitaniS. Selective up-regulation of phospholipase C-ß2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors. J Leukoc Biol71:957–965, 2002.
123.
NimubonaSGruloisIBernardMDrenouBGodardMFauchetRLamyT. Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: report on three cases. Leukemia16:1871–1873, 2002.
124.
EgyedMMihalyfalviZKollarBRumiGKellerEVassJFeketeS. Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon. Orv Hetil142:2421–2425, 2001.
125.
BenthinMDallmannIAtzpodienJ. 13-Cis- and all trans-retinoic acid have antiproliferative effects on CML cells and render IFN-α antiproliferative potency after combined treatment in vitro. Cancer Biother Radiopharm16:323–331, 2001.
126.
RobinsonKLAyelloJHughesRVen van deCIssittLKurtzbergJCairoMS. Ex vivo expansion maturation and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti CD3, and IL-7: potential for adoptive immunotherapy post-umbilical cord blood transplantation. Exp Hematol30:245–251, 2002.
127.
GluckmanE. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol28:1197–1205, 2000.
128.
Abu-GhoshAGoldmanSSloneVvan de VenCSuenYMurphyLSenderLCairoM. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-vs-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplant24:535–544, 1999.
129.
ThompsonJAGillilandDGPrchalJTBennettJMLarholtKNelsonRARoseEHDuganMH. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood95:1175–1179, 2000.
130.
O'brienSGGuilhotFLarsonRAGathmannIBaccaraniMCervantesFCornelissenJJFischerTHochhausAHughesTLechnerKNielsenJLRousselotPReiffersJSaglioGShepherdJSimonssonBGratwohlAGoldmanJMKantarjianHTaylorKVerhoefGBoltonAECapdevilleRDrukerBJ. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med348:994–1004, 2003.
131.
MohamedANPembertonPZonderJSchifferCA. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res9:1333–1337, 2003.
132.
McNamaraCGriggASzerJRobertsACampbellLHoytRLynchKJunejaS. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. Clin Lab Haematol25:119–125, 2003.
133.
KantarjianHTalpazMO'brienSGilesFBeth RiosMWhiteKGarcia-ManeroGFerrajoliAVerstovsekSWierdaWKornblauSCortesJ. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer97:2225–2228, 2003.
134.
EconomopoulosTFountzilasGPavlidisNKalantzisDPapageorgiouEChristodoulouCHamilosGNicolaidesCDimopoulosM. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J4:110–115, 2003.
135.
HansenACPedersenFS. Safety features of retroviral vectors. Curr Opin Mol Ther4:324–333, 2002.
136.
KoyaRCKasaharaNPullarkatVLevineAMStripeckeR. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia16:1645–1654, 2002.
137.
TurturroF. Recombinant adenovirus-mediated cytotoxic gene therapy and lymphoproliferative disorders: analysis based on pharmacodynamics. Curr Drug Targets Immune Endocr Metabol Disord2:109–118, 2002.
138.
OtsuMSugamuraKCandottiF. Lack of dominant-negative effects of a truncated γc on retroviral-mediated gene correction of immunodeficient mice. Blood97:1618–1624, 2001.
139.
KhonDBSadelainMGloriosoJC. Occurrence of leukemia following gene therapy of X-linked SCID. Nat Rev Cancer3:477–488, 2003.
140.
SaudemontABuffenoirGDenysADesreumauxPJouyNHetuinDBautersFFenauxPQuesnelB. Gene transfer of CD 154 and IL-12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia16:1637–1644, 2002.
141.
KippsTJ. Immune and cell therapy of hematologic malignancies. Int J Hematol Suppl1:269–273, 2002.
142.
WildaMFuchsUWossmannWBorkhardtA. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene21:5716–5724, 2002.
143.
DarleyRLBurnettAK. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Exp Hematol27:1599–1608, 1999.
144.
Van DammeAVanden DriesscheTCollenDChuahMK. Bone marrow stromal cells as targets for gene therapy. Curr Gene Ther2:195–209, 2002.
